Calgary, Alberta--(Newsfile Corp. - August 13, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or ...

The MarketWatch News Department was not involved in the creation of this content. SPG601 is a first-in-class, BK-modulator with the potential to improve cognitive, emotional and sensory symptoms in ...

For 22 years, Jason Mazzola’s life was defined by Fragile X, a genetic condition that often causes autism and intellectual disability. Jason, who is 24 now, needed constant supervision. He had ...

Nospharma announces a new strategic partnership with the the FRAXA Research Foundation to conduct pre-clinical testing of NOS-01, a potential new treatment for Fragile X Syndrome. This partnership ...

Only about 5% of rare diseases have an effective treatment. Among the other 95% is fragile X syndrome, a genetic disorder and leading cause of autism. The search for a cure has been at turns both ...

There is still no cure for Fragile X Syndrome—the most common genetically inherited cause of intellectual disabilities—despite the fact that the underlying cause (a mutation in a single gene, FMR1) ...

SPG601 is a first-in-class, BK-modulator with the potential to improve cognitive, emotional and sensory symptoms in FXS patients FRAXA's early preclinical support helped establish the ...

FRAXA's early preclinical support helped establish the calcium-activated potassium ("BK") channel modulator mechanism behind SPG601. FRAXA also supported the development of another BK channel ...